Updating the Fundamentals on Cellular Biomedicine Group Inc. (NASDAQ:CBMG)


Cellular Biomedicine Group Inc. (NASDAQ:CBMG) has posted results for the last fiscal year, recording EPS of $-2.14. For this year, EPS is anticipated to grow -23.20% over the preceding year, while next year?s EPS is predicted to increase -2.80%.

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction. Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

Recently, Cellular Biomedicine Group Inc. (NASDAQ:CBMG) reported that for the previous five years, EPS at Cellular Biomedicine Group Inc. has increased -32.90%, while rise sales have surged 77.60% over the same period.

Shares of Cellular Biomedicine Group Inc. are now trading at $7.95, giving it market cap of $100.81M. Over the last 12 months, shares of Cellular Biomedicine Group Inc. have risen to maximum of $-49.33% and declined to a minimum of $57.43%.

The stock’s beta, which measures volatility, is 3.05. For the purpose of clarity, note that a beta of less than 1 implies that a stock is less volatile versus the overall market, while a beta over 1 indicates a stock is more volatile over the market.

Cellular Biomedicine Group Inc. shows 20-Day Simple Moving Average of $2.32% and 50-Day Simple Moving Average of $-18.94%. The 200-Day SMA is $-35.55%.

The stock’s weekly performance is 30.33% while its monthly performance is -25.70%. Year-to-date the equity has moved -39.31% compared to a performance of -47.66% over the preceding 12 months.

Cellular Biomedicine Group Inc. has witnessed 0.00% insider transactions, showing insider ownership of 1.20%. That compares to 9.90% ownership by institutional investors after -4.78% institutional transactions.

Return on investments in Cellular Biomedicine Group Inc. for the last 12 months is -43.10%, while return on assets for the equivalent period is -41.20%. Return on equity for the previous 12 months, on the other hand, is -42.60%.

Cellular Biomedicine Group Inc. has RSI (Relative Strength Index) of 49.41.

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the Company’s Board of Directors (the “Board”) has approved a new stock repurchase program granting the company authority to repurchase up to $10 million in common shares (the “2017 Stock Repurchase Program”) through open market purchases pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and in accordance with Rule 10b-18 of the Exchange Act.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.